Recent Updates
Recently added Catalysts
CMPS Positive Sentiment

Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026

Tuesday, October 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Compass Pathways plc will announce its third quarter financial results on November 3, 2026. The report will cover results for the quarter ending September 30, 2026. Additionally, management will host a conference call to discuss the results and recent developments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Compass Pathways is focused on mental health care.
  • The company is set to announce financial results.
  • Management will provide updates on recent developments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+172%
120-day peak, hindsight
Typical move
8.6%
average across 3 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
COMP360
Phase 3 · Treatment Resistant Depression

Full Press Release Details

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the third quarter ended September 30, 2026, and provide an update on recent developments, on November 3, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 3, 2026. A live webcast of the call will be available

Frequently Asked Questions

When will Compass Pathways announce its Q3 2026 results?

Compass Pathways will announce its Q3 2026 results on November 3, 2026.

What time is the conference call for Q3 results?

The conference call will be held at 8:00 am ET on November 3, 2026.

Where can I watch the conference call?

A live webcast of the conference call will be available.

What will be discussed during the conference call?

The call will cover financial results and recent developments.

ShareAdd on Google
Tags: CMPS Compass Pathways financial results mental health biotechnology
Last updated: Oct 27, 2026

Biotech snapshot

Cash runway
$433M liquidity · $13M/mo burn
~30 mo
Minimal dilution risk
Lead asset
COMP360Phase 3
Treatment Resistant Depression →

Catalyst track record

+172%
best trade around CMPS's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for CMPS.

See every catalyst's timing & PoA →